Top Health Tech Companies in Bangalore (125)

Strong Revenue Growth: Company-reported results indicate 34% year-over-year software growth in 2024, alongside earlier periods of 100% YoY elluminate software growth in 2022 and 50% in 2021. These signals point to sustained momentum in the software business.

Market Expansion: The organization added 20 net-new clients in 2024 and more than 20 in 2025, with its footprint among top global pharma expanding from 16 to 18 of the world’s top 50 companies. This reflects a widening customer base across large enterprise accounts.

Investor Backing & Capital Strength: A September 2024 majority investment by GI Partners—described as a growth investment—with previous investor Summit Partners retaining a minority stake indicates strong institutional support. Subsequent expansion of the executive team aligns with funding to drive the next phase of growth.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Profitability: Adjusted profitability improved, with Q1 2026 adjusted EBITDA higher than the prior year and full‑year 2026 adjusted EBITDA guidance raised. Non‑GAAP earnings improved even as GAAP results were affected by non‑cash goodwill impairments.

Healthy Cash Flow: Operating cash flow was positive in Q1 2026, and trailing twelve‑month unlevered free cash flow was cited at roughly $49.9 million. Cash generation remained positive through 2025, providing support during the top‑line transition.

Cost & Operational Efficiency: Expense discipline and restructuring helped expand margins and deliver results at or above the high end of guidance in late 2025 and Q1 2026. Management is emphasizing efficiency while continuing targeted investments in product, integrations, and AI features.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Strong Market Position & Advantage: GE HealthCare is positioned as a top-tier global medical technology player with leadership across diagnostic imaging, ultrasound, and pharmaceutical diagnostics, supported by a very large installed base and operations in over 160 countries. Scale and portfolio breadth across major modalities and care settings are repeatedly presented as durable advantages that support recurring service, upgrades, and consumables/software revenue.

Innovation-Driven Growth: R&D investment exceeding $1B annually and an active pipeline of many products in imaging, digital health, and in vitro diagnostics indicate a sustained innovation engine. The emphasis on AI-enabled devices and new product introductions (e.g., photon-counting CT and other launches) is framed as a multi-year driver that should increase contribution to revenue over time.

Resilient & Sustainable Growth: Orders and backlog signals (book-to-bill above 1.0, growing orders, and a reported record backlog) suggest demand is keeping pace with shipments and provides forward visibility. Guidance for continued low-single-digit organic growth alongside expectations for EPS growth and meaningful free cash flow points to steady, defensible expansion rather than cyclical contraction.

Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.

Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.

Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.

Strong Revenue Growth: Comparable revenue increased in FY2025 and the company reports a positive start to FY2026 on a comparable basis while reaffirming its full-year comparable growth guidance.

Profitability: Adjusted EBIT margin rose in FY2025, and free cash flow improved alongside a higher proposed dividend, indicating strengthened operating performance and shareholder returns.

Strong Market Position & Advantage: The company is positioned as a leader in medical technology, with noted dominance in diagnostic imaging and continued momentum in Imaging and Precision Therapy helping sustain growth despite pressures elsewhere.

Profitability: Adjusted EPS from continuing operations rose in the latest quarter and gross margin expanded year over year, with materials attributing gains to productivity and mix. Transformation initiatives are presented as supporting margin expansion and earnings growth even when reported sales are muted.

Healthy Cash Flow: Operating cash flow increased meaningfully year to date versus the prior period, and total debt declined, signaling strengthened liquidity. Cash generation is described as improving alongside margin gains.

Strong Market Position & Advantage: Brands such as Huggies and Kleenex hold leading share positions across many countries, and recent updates highlight holding or gaining share in a majority of tracked markets. This footprint and momentum indicate durable category advantage despite competitive intensity.

Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.

Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.

Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.

Strong Market Position & Advantage: Strong market positioning is reinforced by repeated “Best in KLAS” recognition and being described as a leader in ambulatory EHR/practice management for independent physician practices. Broad adoption among ambulatory providers and large-scale deployments support a durable competitive edge in its core segment.

Innovation-Driven Growth: Innovation-driven momentum is emphasized through an AI-native roadmap and multiple AI feature launches across EHR, documentation, patient communications, and revenue-cycle workflows. Interoperability initiatives (including TEFCA migration) further strengthen platform stickiness and scalability.

Resilient & Sustainable Growth: Resilience is reflected in continued organic growth and expectations of mid- to high-single-digit revenue increases despite temporary disruptions such as the 2024 Change Healthcare cyberattack. Forecasts for expanding EBITDA and a shift to positive free operating cash flow in 2025 support a stable growth trajectory.